Indication

Synergy for skin and skin structure Pseudomonas aeruginosa infection

The phrase "synergy for skin and skin structure *Pseudomonas aeruginosa* infection" is not a standardized clinical diagnostic entity, but rather describes a pharmacotherapeutic strategy or microbiological phenomenon in the management of integumentary infections caused by the opportunistic Gram-negative pathogen *Pseudomonas aeruginosa*. Read more about Synergy for skin and skin structure Pseudomonas aeruginosa infection

12 drugs 11 manufacturers

Advertisement

Drugs that treat it

Common Synergy for skin and skin structure Pseudomonas aeruginosa infection therapies.

Showing 10–12 of 12 drugs

GENTAMICIN SULFATE

AMINOGLYCOSIDES, PARENTERAL·SEPSIS CAUSED BY ENTEROBACTER·+63
EUGIA US LLC

GENTAMICIN SULFATE

AMINOGLYCOSIDES, PARENTERAL·SEPSIS CAUSED BY ENTEROBACTER·+63
Hikma Pharmaceuticals USA

GENTAMICIN SULFATE

AMINOGLYCOSIDES, PARENTERAL·SEPSIS CAUSED BY ENTEROBACTER·+63
FRESENIUS KABI
Filter & compare in the drug finder →Opens the drug finder with Synergy for skin and skin structure Pseudomonas aeruginosa infection preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Synergy for skin and skin structure Pseudomonas aeruginosa infection.

The phrase "synergy for skin and skin structure *Pseudomonas aeruginosa* infection" is not a standardized clinical diagnostic entity, but rather describes a pharmacotherapeutic strategy or microbiological phenomenon in the management of integumentary infections caused by the opportunistic Gram-negative pathogen *Pseudomonas aeruginosa*.

Cutaneous and subcutaneous infections commonly occur in vulnerable populations—such as patients with extensive thermal burns, chronic diabetic ulcers, surgical wounds, or neutropenia—where disrupted skin barriers and impaired local immunity permit bacterial invasion.

In this clinical state, *P.

aeruginosa* produces extensive tissue necrosis, microvascular thrombosis, or refractory biofilms through virulence factors like exotoxin A, elastases, and pyocyanin, frequently manifesting as hemorrhagic bullae, ecthyma gangrenosum, or deep-seated ulcerations.

The qualification of synergy refers to the enhanced, supra-additive bactericidal effect achieved when specific antimicrobial agents are combined, which is clinically utilized to overcome intrinsic and acquired multidrug resistance mechanisms in complicated or polymicrobial skin infections.

Personalize your experience

Follow Synergy for skin and skin structure Pseudomonas aeruginosa infection and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it